References
1. Gupta A, Hughes MD, Garcia-Prats AJ, McIntire K, Hesseling AC.
Inclusion of key populations in clinical trials of new antituberculosis
treatments: Current barriers and recommendations for pregnant and
lactating women, children, and HIV-infected persons. PLoS Med
[Internet]. 2019;16(8):1–26. Available from:
http://dx.doi.org/10.1371/journal.pmed.1002882
2. WHO. WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment
- Drug-Resistant Tuberculosis Treatment [Internet]. 2021 [cited
2021 Oct 12]. Available from:
https://www.who.int/publications/i/item/9789240007048
3. Schalkwijk S, Greupink R, Burger D. Free dug concentrations in
pregnancy: Bound to measure unbound? Br J Clin Pharmacol.
2017;83(12):2595–8.
4. van Heeswijk RPG, Dannemann B, Hoetelmans RMW. Bedaquiline: a review
of human pharmacokinetics and drug-drug interactions. J Antimicrob
Chemother. 2014 Sep;69(9):2310–8.
5. Lim FH, Lovering AM, Currie A, Jenkins DR. Linezolid and lactation:
measurement of drug levels in breast milk and the nursing infant. J
Antimicrob Chemother. 2017;72(9):2677–8.
6. Cahill JB, Bailey EM, Chien S, Johnson GM. Levofloxacin secretion in
breast milk: A case report. Pharmacotherapy. 2005;25(1):116–8.
7. Tran J, Montakantikul P. The safety of antituberculosis medications
during breastfeeding. J Hum Lact. 1998;14(4):337–40.
8. Loveday M, Hlangu S, Furin J. Breastfeeding in women living with
tuberculosis. Int J Tuberc Lung Dis. 2020;24(9):880–91.
9. Ozturk Z, Tatliparmak A. Leprosy treatment during pregnancy and
breastfeeding: A case report and brief review of literature. Dermatol
Ther. 2017;30(1):2016–7.
10. FDA. Full prescribing information: SIRTURO [Internet]. [cited
2021 Oct 12]. Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/204384s000lbl.pdf
11. Gupta A, Mathad JS, Abdel-Rahman SM, Albano JD, Botgros R, Brown V,
et al. Toward Earlier Inclusion of Pregnant and Postpartum Women in
Tuberculosis Drug Trials: Consensus Statements from an International
Expert Panel. Clin Infect Dis. 2015;62(6):761–9.
12. Gupta A, Hughes MD, Garcia-Prats AJ, McIntire K, Hesseling AC.
Inclusion of key populations in clinical trials of new antituberculosis
treatments: Current barriers and recommendations for pregnant and
lactating women, children, and HIV-infected persons. PLoS Med.
2019;16(8):1–26.
13. Loveday M, Hughes J, Sunkari B, Master I, Hlangu S, Reddy T, et al.
Maternal and Infant Outcomes among Pregnant Women Treated for
Multidrug/Rifampicin-Resistant Tuberculosis in South Africa. Clin Infect
Dis. 2021;72(7):1158–68.
14. Brill MJE, Svensson EM, Pandie M, Maartens G, Karlsson MO.
Confirming model-predicted pharmacokinetic interactions between
bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV
and drug-resistant tuberculosis. Int J Antimicrob Agents.
2017;49(2):212–7.
15. Boeckmann AJ, Beal SL, Sheiner LB. NONMEM User’s Guide, Part V.
Introductory Guide. NONMEM Proj Gr. 2011;(April):48.
16. Keizer RJ, Karlsson MO, Hooker A. Modeling and Simulation Workbench
for NONMEM: Tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst
Pharmacol. 2013 Jun;2(6):e50.
17. Ngwalero P, Brust JCM, van Beek SW, Wasserman S, Maartens G,
Meintjes G, et al. Relationship between Plasma and Intracellular
Concentrations of Bedaquiline and Its M2 Metabolite in South African
Patients with Rifampin-Resistant Tuberculosis. Antimicrob Agents
Chemother [Internet]. 2021 Oct 18;65(11):e0239920. Available from:
https://journals.asm.org/doi/10.1128/AAC.02399-20
18. Wilson JT. Determinants and Consequences of Drug Excretion in Breast
Milk. Drug Metab Rev. 1983 Jan;14(4):619–52.
19. Koren G. Maternal-Fetal Toxicology: A Clinician’s Guide. Third edit.
Vol. 149, Archives of Pediatrics & Adolescent Medicine. New York:
American Medical Association; 1995. 177–221 p.
20. Chan Kwong AHXP, Calvier EAM, Fabre D, Gattacceca F, Khier S. Prior
information for population pharmacokinetic and
pharmacokinetic/pharmacodynamic analysis: overview and guidance with a
focus on the NONMEM PRIOR subroutine. Journal of Pharmacokinetics and
Pharmacodynamics. 2020. p. 1–16.
21. Svensson EM, Aweeka F, Park J-G, Marzan F, Dooley KE, Karlsson MO.
Model-Based Estimates of the Effects of Efavirenz on Bedaquiline
Pharmacokinetics and Suggested Dose Adjustments for Patients Coinfected
with HIV and Tuberculosis. Antimicrob Agents Chemother. 2013
Jun;57(6):2780–7.
22. Feghali MN, Mattison DR. Clinical Therapeutics in Pregnancy. J
Biomed Biotechnol. 2011 Jul;2011:1–13.
23. Eke AC, Olagunju A, Momper J, Penazzato M, Abrams EJ, Best BM, et
al. Optimizing Pharmacology Studies in Pregnant and Lactating Women
Using Lessons From HIV: A Consensus Statement. Clin Pharmacol Ther.
2021;110(1):36–48.
24. Nachega JB, Uthman OA, Anderson J, Peltzer K, Wampold S, Cotton MF,
et al. Adherence to antiretroviral therapy during and after pregnancy in
low-income, middle-income, and high-income countries: A systematic
review and meta-analysis. Aids. 2012;26(16):2039–52.
25. Chaves RG, Lamounier JA. Uso de medicamentos durante a lactação. J
Pediatr (Rio J). 2004 Nov;80(5):s189–98.
26. Feng X, Zhu W, Schurig-Briccio LA, Lindert S, Shoen C, Hitchings R,
et al. Antiinfectives targeting enzymes and the proton motive force.
Proc Natl Acad Sci. 2015 Dec;112(51):E7073–82.
27. Howard CR, Lawrence RA. Drugs and Breastfeeding. Clin Perinatol.
1999 Jun;26(2):447–78.
28. Svensson EM, Murray S, Karlsson MO, Dooley KE. Rifampicin and
rifapentine significantly reduce concentrations of bedaquiline, a new
anti-TB drug. J Antimicrob Chemother. 2014;70(4):1106–14.
29. Iscan M, Klaavuniemi T, Çoban T, Kapucuo˘ Glu N, Pelkonen O, Raunio
H. The expression of cytochrome P450 enzymes in human breast tumours and
normal breast tissue. Breast Cancer Res Treat. 2001;70:47–54.
30. Hellmold H, Rylander T, Magnusson M, Reihnér E, Warner M, Gustafsson
J-A. Characterization of Cytochrome P450 Enzymes in Human Breast Tissue
from Reduction Mammaplasties. J Clin Endocrinol Metab. 1998
Mar;83(3):886–95.
31. Huang Z, Fasco MJ, Figge HL, Keyomarsi K, Kaminsky LS. Expression of
cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos.
1996;24(8).
Table 1: Characteristics of pregnant women treated for
rifampicin-resistant tuberculosis